PMV Pharmaceuticals, Inc.

NasdaqGS PMVP

PMV Pharmaceuticals, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -1.36

PMV Pharmaceuticals, Inc. Price to Earnings Ratio (P/E) is -1.36 on January 14, 2025, a 14.14% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

PMV Pharmaceuticals, Inc. 52-week high Price to Earnings Ratio (P/E) is -1.17 on February 14, 2024, which is 13.79% above the current Price to Earnings Ratio (P/E).
PMV Pharmaceuticals, Inc. 52-week low Price to Earnings Ratio (P/E) is -1.79 on November 07, 2024, which is -31.85% below the current Price to Earnings Ratio (P/E).
PMV Pharmaceuticals, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.51.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: PMVP

PMV Pharmaceuticals, Inc.

CEO	Dr. David H. Mack Ph.D.
IPO Date	Sept. 25, 2020
Location	United States
Headquarters	8 Clarke Drive
Employees	63
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

Key trends

Past 5 years